Payment overview · 2025
General Payments
$1,089.98
62 reported records · 15 companies
Healthcare provider profile · identity verified
Mark A Roberts, MD
Allopathic & Osteopathic Physicians|Family Medicine|Hospice and Palliative Medicine · EVERGREEN, AL · NPI 1275565442
Verified facts
What the public records show
CMS Open Payments records show Mark A Roberts, MD received $1,089.98 in general payments during 2025 across 62 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Jardiance, Mounjaro, Rexulti, Shingrix, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 246 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Viberzi by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 291 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 291 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $213.46 | 19.6% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $194.61 | 17.9% | 14 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $141.41 | 13.0% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $138.73 | 12.7% | 7 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $78.20 | 7.2% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $71.63 | 6.6% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $54.40 | 5.0% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $53.03 | 4.9% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.83 | 2.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.91 | 2.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.31 | 1.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 1.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.31 | 1.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.77 | 1.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.53 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,071.13 | 61 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $179.34 | 13 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $141.41 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $127.16 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $104.67 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $99.08 | 6 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $78.20 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $77.27 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $71.63 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $54.40 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $53.03 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $40.73 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $34.12 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $30.83 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.77 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $11.57 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $11.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 37 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 291 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 136 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 90 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 147 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 93 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 119 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
115 | 30 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
246 | 63 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
136 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 25 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
291 | 39 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
37 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
93 | 82 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
119 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
147 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
65 | 15 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
35 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
291 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1458 | 186 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1013 | 266 |
| Potassium Chloride | Potassium Chloride | 806 | 184 |
| Amlodipine Besylate | Amlodipine Besylate | 736 | 194 |
| Pantoprazole Sodium | Pantoprazole Sodium | 734 | 182 |
| Furosemide | Furosemide | 667 | 182 |
| Levothyroxine Sodium | Levothyroxine Sodium | 575 | 115 |
| Gabapentin | Gabapentin | 503 | 123 |
| Allopurinol | Allopurinol | 484 | 124 |
| Omeprazole | Omeprazole | 422 | 104 |
| Tamsulosin Hcl | Tamsulosin Hcl | 393 | 97 |
| Hydrochlorothiazide | Hydrochlorothiazide | 386 | 87 |
| Quetiapine Fumarate | Quetiapine Fumarate | 383 | 90 |
| Diclofenac Sodium | Diclofenac Sodium | 380 | 103 |
| Metoprolol Succinate | Metoprolol Succinate | 377 | 95 |
| Metoprolol Tartrate | Metoprolol Tartrate | 369 | 90 |
| Xarelto | Rivaroxaban | 363 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 353 | 106 |
| Oxycodone Hcl | Oxycodone Hcl | 318 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 317 | 114 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 301 | 236 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 295 | 51 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 293 | 89 |
| Clopidogrel | Clopidogrel Bisulfate | 291 | 69 |
| Eliquis | Apixaban | 291 | 39 |
| Donepezil Hcl | Donepezil Hcl | 288 | 61 |
| Carvedilol | Carvedilol | 273 | 68 |
| Losartan Potassium | Losartan Potassium | 261 | 64 |
| Clonidine Hcl | Clonidine Hcl | 260 | 57 |
| Famotidine | Famotidine | 252 | 86 |
| Metformin Hcl | Metformin Hcl | 249 | 77 |
| Synthroid | Levothyroxine Sodium | 246 | 63 |
| Montelukast Sodium | Montelukast Sodium | 228 | 60 |
| Sucralfate | Sucralfate | 225 | 58 |
| Alprazolam | Alprazolam | 216 | 36 |
| Prednisone | Prednisone | 211 | 119 |
| Cefdinir | Cefdinir | 210 | 161 |
| Tramadol Hcl | Tramadol Hcl | 209 | 65 |
| Mirtazapine | Mirtazapine | 202 | 41 |
| Lisinopril | Lisinopril | 201 | 56 |
| Duloxetine Hcl | Duloxetine Hcl | 198 | 43 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 198 | 122 |
| Meclizine Hcl | Meclizine Hcl | 191 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 190 | 51 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 185 | 31 |
| Celecoxib | Celecoxib | 175 | 39 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 172 | 43 |
| Trazodone Hcl | Trazodone Hcl | 168 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 166 | 33 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 156 | 41 |
| Doxycycline Hyclate | Doxycycline Hyclate | 149 | 88 |
| Ondansetron Odt | Ondansetron | 149 | 77 |
| Fluticasone Propionate | Fluticasone Propionate | 147 | 44 |
| Mounjaro | Tirzepatide | 147 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 145 | 37 |
| Ozempic | Semaglutide | 145 | 25 |
| Farxiga | Dapagliflozin Propanediol | 136 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 135 | 27 |
| Levofloxacin | Levofloxacin | 133 | 116 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 130 | 88 |
| Ibuprofen | Ibuprofen | 129 | 39 |
| Clonazepam | Clonazepam | 125 | 21 |
| Lorazepam | Lorazepam | 124 | 36 |
| Memantine Hcl | Memantine Hcl | 124 | 22 |
| Mupirocin | Mupirocin | 124 | 63 |
| Simvastatin | Simvastatin | 121 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 119 | 28 |
| Linzess | Linaclotide | 115 | 30 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 114 | 25 |
| Aripiprazole | Aripiprazole | 111 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 110 | 31 |
| Megestrol Acetate | Megestrol Acetate | 109 | 47 |
| Atenolol | Atenolol | 107 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 106 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 103 | 22 |
| Fluconazole | Fluconazole | 102 | 53 |
| Candesartan Cilexetil | Candesartan Cilexetil | 101 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 100 | 27 |
| Levetiracetam | Levetiracetam | 98 | 16 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 98 | 19 |
| Pregabalin | Pregabalin | 97 | 31 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 93 | 82 |
| Albuterol Sulfate | Albuterol Sulfate | 92 | 17 |
| Amoxicillin | Amoxicillin | 92 | 54 |
| Meloxicam | Meloxicam | 91 | 25 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 90 | 11 |
| Jardiance | Empagliflozin | 90 | 25 |
| Azithromycin | Azithromycin | 88 | 76 |
| Finasteride | Finasteride | 86 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 82 | 37 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 82 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 79 | 22 |
| Myrbetriq | Mirabegron | 78 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 76 | 17 |
| Spironolactone | Spironolactone | 76 | 21 |
| Methylprednisolone Acetate | Methylprednisolone Acetate | 74 | 35 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 74 | 45 |
| Vascepa | Icosapent Ethyl | 74 | 21 |
| Metolazone | Metolazone | 73 | 16 |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 72 | 36 |
| Risperidone | Risperidone | 72 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 69 | 19 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 69 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 66 | 17 |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 66 | 20 |
| Trulicity | Dulaglutide | 65 | 15 |
| Midodrine Hcl | Midodrine Hcl | 63 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 63 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 61 | 52 |
| Estradiol | Estradiol | 61 | 18 |
| Indomethacin | Indomethacin | 61 | 18 |
| Januvia | Sitagliptin Phosphate | 61 | suppressed |
| Kerendia | Finerenone | 58 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 56 | 31 |
| Fenofibrate | Fenofibrate | 55 | 15 |
| Cefprozil | Cefprozil | 54 | 42 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 14 |
| Valacyclovir | Valacyclovir Hcl | 54 | 20 |
| Dexamethasone | Dexamethasone | 53 | 34 |
| Lidocaine Hcl | Lidocaine Hcl | 53 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 53 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 51 | 12 |
| Lidocaine | Lidocaine | 51 | 12 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 51 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 50 | suppressed |
| Diazepam | Diazepam | 50 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 50 | 19 |
| Nitroglycerin | Nitroglycerin | 50 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 50 | 21 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 49 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 47 | 15 |
| Terbinafine Hcl | Terbinafine Hcl | 46 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 45 | 16 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 45 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 45 | 27 |
| Propranolol Hcl | Propranolol Hcl | 45 | 12 |
| Baclofen | Baclofen | 44 | 17 |
| Divalproex Sodium | Divalproex Sodium | 44 | suppressed |
| Loperamide | Loperamide Hcl | 44 | 20 |
| Nystatin | Nystatin | 44 | 26 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 42 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 12 |
| Methylprednisolone | Methylprednisolone | 42 | 40 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Rexulti | Brexpiprazole | 41 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | 12 |
| Sertraline Hcl | Sertraline Hcl | 40 | suppressed |
| Temazepam | Temazepam | 40 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | 15 |
| Valsartan | Valsartan | 39 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 38 | 13 |
| Metformin Hcl Er | Metformin Hcl | 38 | 15 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 37 | 37 |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Novolog | Insulin Aspart | 37 | suppressed |
| Topiramate | Topiramate | 37 | suppressed |
| Tradjenta | Linagliptin | 37 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | suppressed |
| Ubrelvy | Ubrogepant | 37 | suppressed |
| Fentanyl | Fentanyl | 36 | suppressed |
| Hydrocortisone | Hydrocortisone | 36 | suppressed |
| Invokana | Canagliflozin | 36 | suppressed |
| Latanoprost | Latanoprost | 36 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 36 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 35 | 35 |
| Cilostazol | Cilostazol | 34 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 34 | 27 |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Digoxin | Digoxin | 33 | suppressed |
| Glimepiride | Glimepiride | 33 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Primidone | Primidone | 32 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 32 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 31 | suppressed |
| Oxycontin | Oxycodone Hcl | 31 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 30 | suppressed |
| Ezetimibe | Ezetimibe | 30 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 30 | suppressed |
| Methimazole | Methimazole | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 29 | suppressed |
| Torsemide | Torsemide | 29 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 29 | suppressed |
| Clonidine | Clonidine | 28 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 28 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 27 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Carisoprodol | Carisoprodol | 26 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 26 | suppressed |
| Fycompa | Perampanel | 26 | suppressed |
| Methadone Hcl | Methadone Hcl | 26 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 26 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 25 | suppressed |
| Demeclocycline Hcl | Demeclocycline Hcl | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Folic Acid | Folic Acid | 25 | 12 |
| Lactulose | Lactulose | 25 | suppressed |
| Roflumilast | Roflumilast | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 24 | suppressed |
| Metronidazole | Metronidazole | 23 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Ibu | Ibuprofen | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Vraylar | Cariprazine Hcl | 21 | suppressed |
| Budesonide | Budesonide | 20 | suppressed |
| Etodolac | Etodolac | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 19 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 19 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 19 | 16 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 18 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Humalog | Insulin Lispro | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 17 | 14 |
| Lovastatin | Lovastatin | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 16 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 16 | 13 |
| Novolin R | Insulin Regular, Human | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Viberzi | Eluxadoline | 16 | suppressed |
| Cartia Xt | Diltiazem Hcl | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 12 |
| Colchicine | Colchicine | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Klor-Con 10 | Potassium Chloride | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Constulose | Lactulose | 13 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Verquvo | Vericiguat | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Butrans | Buprenorphine | 12 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Ztlido | Lidocaine | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Hysingla Er | Hydrocodone Bitartrate | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,089.98 · 62 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Korlym, MOUNJARO, NURTEC ODT, REXULTI, SHINGRIX, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, ZAVZPRET, ZEPBOUND | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error